Adaptimmune Therapeutics PLC Sponsored ADR(NASDAQ : ADAP)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | 0.86% | 122.37 | 1.1% | $687.52m | |
| GILD | Gilead Sciences, Inc. | -1.28% | 80.17 | 0.9% | $652.57m | |
| AMGN | Amgen Inc. | -1.33% | 180.53 | 1.1% | $453.70m | |
| BIIB | Biogen Inc. | -2.83% | 328.55 | 1.2% | $418.30m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.05% | 432.76 | 2.7% | $322.07m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -2.31% | 151.06 | 1.9% | $219.47m | |
| INCY | Incyte Corporation | -0.62% | 113.48 | 2.5% | $198.97m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -2.75% | 135.20 | 1.9% | $188.62m | |
| ILMN | Illumina, Inc. | 0.80% | 211.55 | 3.5% | $133.98m | |
| ALNY | Alnylam Pharmaceuticals, Inc | 0.76% | 115.57 | 10.7% | $131.21m | |
| EXEL | Exelixis, Inc. | -0.70% | 26.98 | 6.5% | $126.80m | |
| BLUE | Bluebird Bio, Inc. | -1.54% | 140.35 | 17.3% | $119.91m | |
| SRPT | Sarepta Therapeutics, Inc. | -0.91% | 51.47 | 16.9% | $110.18m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.47% | 86.46 | 4.4% | $109.02m | |
| CLVS | Clovis Oncology, Inc. | -2.49% | 75.57 | 16.5% | $96.52m |
Company Profile
Adaptimmune Therapeutics Plc is a clinical stage biopharmaceutical company, which focuses on novel cancer immunotherapy products based on T-cell receptor platform. Its TCR platform targets NY-ESO-1 cancer antigen. The company was founded in December 2014 and is headquartered in Oxford, the United Kingdom.